CD8A and viral infectious disease: As the administration of VACV equates to an induced viral infection, which triggers effective antiviral cytotoxic T cell responses, we postulated that the increased T cell responses, especially CD8+ T cell responses, seen following intratumoral mJX-594 treatment may have included anticancer-specific CD8+ T cell responses.